



John E. Baldacci, Governor      Brenda M. Harvey, Commissioner

Department of Health and Human Services  
 MaineCare Services  
 442 Civic Center Drive  
 # 11 State House Station  
 Augusta, Maine 04333-0011  
 Tel: 1-866-796-2463; Fax: (207) 287-8601  
 TTY: 1-800-423-4331

TO:            Maine DUR Board  
 FROM:        Shari Martin  
 DATE:        APRIL 30, 2009

RE:            Maine DUR Board meeting minutes from April 14, 2009

Vice Chair, Lisa Wendler called the meeting to order at 6:03 p.m. Introductions were made then the floor was opened up for public comments.

ATTENDANCE	PRESENT	ABSENT	EXCUSED
William Alto, M.D. Dartmouth Family Practice			X
Robert Carroll, R.Ph., Target Pharmacy	X		
Timothy Clifford, M.D., Family Practice, GHS	X		
Mike Ouellette, R.Ph. GHS			X
Steven Meister MD, Pediatrician	X		
Andrew Cook, M.D. Psychiatrist (DBDS)	X		
Amy Enos, Pharm. D. Waltz LTC Pharmacy	X		
Laureen Biczak DO, Infectious Disease, GHS	X		
Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, Maine Medical CTR, Vice-Chair	X		
Mark Braun, M.D., FACP	X		
Jeffrey Barkin, MD Psychiatrist, Chair			X
<b>Non -Voting</b>			
Jennifer Cook, Pharmacy Manager, OMS	X		
Brenda McCormick, Director OMS	X		
Rod Prior MD, Medical Director OMS	X		

**Presenters were in order of sign up.**

**Guests and Guests who signed in and/or presented to the committee:**

Name	Company	Speaker/Topic
Barb Tolbert	Takeda	Kapidex
Sherwana Clarke, Pharm D	Abbott	Trilipix
Tom Algozzine	Pfizer	Toviaz

**Public comments:**

**BARB TOLBERT, TAKEDA (KAPIDEX)(ULORIC):** Presented the board with literature on new Takeda drugs, Kapidex and Uloric. Ms. Tolbert gave specific strength/dosage information. Kapidex can be taken w/o regards to food. She also presented efficacy information and indications for both drugs. In closing Ms. Tolbert requested that the Board consider preferring both Kapidex and Uloric.

**SHERWANNA CLARKE, ABBOTT LABS (TRILIPIX):** Ms. Clarke stated she would like to make two key points about Trilipix. First: Trilipix is the first and only fibric acid derivative FDA approved for combination use with statins. Second key point: No other statins have had this extensive of a study done. Study outcomes were discussed. In closing Ms. Clarke requested that the Board consider adding Trilipix to PDL

**TOM ALGOZZINE, PFIZER (Toviaz):** Mr. Algozzine presented the Board with a handout of "Evaluation of the Utilization of Over Active Bladder Among MaineCare Patients". Mr Algozzine presented his findings on the comparison. He stated that the pattern of use based on daily consumption rates for OAB agents appear consistent with each agents labeling. He also noted that based on his study the utilization trend of Detrol LA and Oxybutyin ER remained flat and overall utilization trend for the class declined during 2008. Mr. Algozzine stated that prevalence of OAB is 16% of the population for 35-64 y.o. This is based on national statistics as he could not find any MaineCare specific data. Requests that the Board consider preferring Toviaz. He noted that Toviaz cannot be split. Mr Algozzine also responded to questions concerning drug-drug interactions.

**Old Business:**

Lisa Wendler asked members to review the draft DUR meeting notes for March. A motion was made to accept the minutes of the March 10, 2009 DUR Board meeting as written. The motion was seconded and passed unanimously.

**Psych Work Group Monthly Update:**

Jennifer stated that the Psych group are getting ready for the annual meeting. She will send out the monthly update to the group.

**New business:**

Dr Clifford noted that while the Board would not normally look at each and every new drug introduced for PDL review that this was being done tonight to familiarize the newer committee members with the overall review process. Individual drug review summaries were passed out and briefly reviewed.

**New Drug Review PDL Status results:**

**Aplenzin** Recommended PDL status non preferred (Board vote: All in favor)

**Astepro-** Recommended PDL status non preferred (Board vote: All in favor)

**Epiduo-** Recommended PDL status non preferred (Board vote: All in favor)

**Kapidex-** Recommended PDL status non preferred (Board vote: All in favor)

**Rapaflo-** Recommended PDL status non preferred (Board vote: All in favor)

**Ryzolt-** Recommended PDL status non preferred (Board vote: All in favor)

**Toviaz-** Recommended PDL status preferred (Board vote: All in favor)

**Uloric-** Recommended PDL status non preferred (Board vote: All in favor)

**Vectical-** Recommended PDL status non preferred (Board vote: All in favor)

**Vimpat-** Recommended PDL status non preferred (Board vote: All in favor)

**Trilipix** reconsideration- Recommended PDL status preferred (Board vote: 7 in favor, 1 abstention)

Dr Braun requested that when Psych drugs are reviewed that the summary include information on the effect size.

**Savella:** New Fibromyalgia indicated drug. It was noted that there is considerable antidepressant useage in Europe. Review tabled until June meeting.

**Closed Session:** Discussed the financial impact of drugs being reviewed including offers for Kapidex and Toviaz. Rediscussed Trilipix in light of new offer.

**Adjournment:** A motion was made and seconded that the meeting be adjourned. All were in favor. The meeting was concluded at 8:30 p.m. The next meeting will be held on May 12, 2009.